Cardiac Electrophysiology and Pacing Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
Cardiac Electrophysiology and Pacing Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
Heart Rhythm. 2023 Jun;20(6):872-878. doi: 10.1016/j.hrthm.2023.03.015. Epub 2023 Mar 17.
Reports of coronary sinus (CS) lead removal include small studies with short implant durations. Procedural outcomes for mature CS leads removed with long duration implantation are unavailable.
The purpose of this study was to examine the safety, efficacy, and clinical predictors of incomplete CS lead removal by transvenous lead extraction (TLE) in a large long implant duration cardiac resynchronization therapy patient cohort.
Consecutive patients with cardiac resynchronization therapy devices in the Cleveland Clinic Prospective TLE Registry who had TLE between 2013 and 2022 were included in the analysis.
CS leads (N = 231; implant duration 6.1 ± 4.0 years) removed from 226 patients were included, using powered sheaths for 137 leads (59.3%). Complete CS lead extraction success was achieved in 95.2% of leads (n = 220) and in 95.6% of patients (n = 216). Major complications occurred in 5 patients (2.2%). Patients who had the CS lead extracted first had significantly higher incomplete removal rates than when the other leads were first removed. Multivariable analysis showed that older CS lead age (odds ratio 1.35; 95% confidence interval 1.01-1.82; P = .03) and removal of the first CS lead (odds ratio 7.48; 95% confidence interval 1.02-54.95; P = .045) were independent predictors of incomplete CS lead removal.
The complete and safe lead removal rate of long implant duration CS leads by TLE was 95%. However, CS lead age and the order in which leads were extracted were the independent predictors of incomplete CS lead removal. Therefore, before the CS lead is extracted, physicians should first extract the leads from the other chambers and use powered sheaths.
有关冠状窦(CS)导联移除的报告包括植入时间较短的小型研究。对于植入时间长的成熟 CS 导联进行移除的程序结果尚不清楚。
本研究的目的是在一个大型心脏再同步治疗患者队列中,检查经静脉导联移除(TLE)对 CS 导联进行长期植入后的安全性、有效性和临床预测因素。
连续纳入 2013 年至 2022 年期间在克利夫兰诊所前瞻性 TLE 登记处接受心脏再同步治疗装置治疗且进行 TLE 的患者。
共纳入 226 例患者的 231 根 CS 导联(植入时间 6.1±4.0 年),其中 137 根(59.3%)使用了动力鞘管。220 根(95.2%)导联和 216 例患者(95.6%)成功实现了 CS 导联完全提取。5 例患者(2.2%)发生了主要并发症。首先移除 CS 导联的患者,其不完全移除率明显高于首先移除其他导联的患者。多变量分析显示,CS 导联年龄较大(比值比 1.35;95%置信区间 1.01-1.82;P=0.03)和首先移除 CS 导联(比值比 7.48;95%置信区间 1.02-54.95;P=0.045)是 CS 导联不完全移除的独立预测因素。
通过 TLE 对植入时间长的 CS 导联进行完全且安全的移除率为 95%。然而,CS 导联年龄和导联移除顺序是 CS 导联不完全移除的独立预测因素。因此,在移除 CS 导联之前,医生应首先从其他腔室中提取导联,并使用动力鞘管。